Institution identification

PURI

https://redirect.ema.europa.eu/resource/1000000009

Institution ID

1000000009

Institution full name and acronym

Merck Healthcare KGaA

Institution countries

Germany

Institution website

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

A Study Assessing the U.S. Post-Marketing Safety Profile of Rebif® in comparison with its U.S. Prescribing Information
An observational, multicenter, prospective, phase IV study evaluating cladribine tablets’ effects on PROs and their correlation with clinical and biometric parameters using Health Technology in subjects with highly-active RMS at their first switch (CLADFIT-MS)
Avelumab in real-world treatment of urothelial cancer – The AVENUE NIS
Disease Registry on Patients with Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Incidence and pattern description of gastrointestinal, skin, genital, corneal, and mucosal erosions, ulcerations, perforations, haemorrhages, fistulas, abscesses, delayed wound healing and death among patients treated with nicorandil with and without diverticular disease
Long-term effectiveness of cladribine in patients previously treated with oral cladribine: a Real-World Evidence analysis using data from the Italian Registry of Multiple Sclerosis (CLARINET-MS)
Non-interventional cohort registry study to assess characteristics and management of patients with Merkel Cell Carcinoma in Germany (MCC-TRIM)
Pergoveris patients’ profile and outcome response measurement in IVF/ICSI autologous cycles (PERFORM)
Prospective Observational Study Aimed at Evaluating Treatment Satisfaction and Effectiveness in Patients with Relapsing Multiple Sclerosis Starting CLADRibinE TAbLets (CLADREAL)
Risk of lactic acidosis with metformin use in type 2 diabetes mellitus with renal impairment: retrospective cohort study